Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 19/20 | 0.52 |
| ▸ | STK17B | O94768 | 15/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937398 | 0.83 | STK17A (0.56) | STK17ASTK17BALDH1A1L3MBTL1 | |
| SCHEMBL1400319 | 0.83 | STK17A (0.56) | STK17ASTK17B | |
| SCHEMBL1937548 | 0.81 | STK17A (0.54) | STK17ASTK17BL3MBTL1 | |
| SCHEMBL20154842 | 0.81 | STK17A (0.60) | STK17ASTK17B | |
| SCHEMBL1938460 | 0.79 | STK17A (0.51) | STK17ASTK17BALDH1A1L3MBTL1 | |
| SCHEMBL1934538 | 0.79 | STK17A (0.51) | STK17ASTK17BALDH1A1L3MBTL1 | |
| SCHEMBL21352293 | 0.76 | STK17A (0.67) | STK17ASTK17B | |
| SCHEMBL21352288 | 0.76 | STK17A (0.63) | STK17ASTK17B | |
| SCHEMBL18488673 | 0.76 | APP (0.50) | STK17ASTK17B | |
| SCHEMBL1938676 | 0.75 | STK17A (0.51) | STK17ASTK17BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| CN-110891954-A | Inhibitors of leucine-rich repeat kinase 2 | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | LRRK2, PARK7, PINK1 | STK17A 264/4885STK17B 204/4885ALDH1A1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.